| Safety and efficacy (effectiveness) of treatment with Avonex
® beyond 3 years is not known. The safety and efficacy
(effectiveness) of Avonex ® in patients with chronic progressive
multiple sclerosis have not been established.
The safety and efficacy (effectiveness) of Avonex ® in
pediatric patients under the age of 18 years have not been evaluated.
Study numbers of patients over the age of 65 years were insufficient
to draw conclusions as to whether they responded differently to Avonex
® than younger patients.
It is unknown whether Avonex ® can affect human reproductive
capacity.
|
